199. Lambert-Eaton Myasthenic Syndrome Flashcards
What is Lambert-Eaton myasthenic syndrome (LEMS)?
An autoimmune channelopathy that results in decreased release of acetylcholine (ACh) at the neuromuscular junction due to autoantibodies against calcium channels.
What occurs at the neuromuscular junction during normal functioning?
An action potential opens voltage-gated calcium channels, allowing calcium ions to enter, bind to proteins on ACh vesicles, prompting the release of ACh.
What is the effect of LEMS on muscle contraction?
Results in muscle weakness due to insufficient ACh release.
What is the approximate prevalence of LEMS?
Affects approximately 1 in 100,000 individuals, with a slightly higher prevalence in males.
At what age does LEMS typically present?
Typically affects persons over the age of 40, but age of onset can vary.
What are the most common neoplasms associated with LEMS?
Small cell lung cancer and gastrointestinal malignancies.
What percentage of individuals with LEMS do not have an associated neoplasm?
Approximately 40%.
What is a distinguishing feature of muscle weakness in LEMS compared to myasthenia gravis (MG)?
LEMS causes proximal limb muscle weakness, worse in lower extremities, while MG affects extraocular and bulbar muscles.
What symptom improvement is observed in LEMS with activity?
Improvement in strength due to buildup of presynaptic calcium.
What autonomic dysfunction symptoms can be associated with LEMS?
Dry mouth, gastroparesis, urinary retention, orthostatic hypotension, erectile dysfunction.
How is LEMS diagnosed?
Through detailed history, physical examination, and electrophysiology.
What is a key diagnostic finding in electromyography (EMG) for LEMS?
An increase in response of more than 60%–100% after exercise.
What imaging should be performed after confirming a diagnosis of LEMS?
Imaging of the chest to rule out small cell lung cancer.
What is the main treatment approach for LEMS associated with neoplasm?
Treating the cancer can result in resolution of LEMS.
What are the two potassium channel blockers approved for LEMS treatment in the U.S.?
- Firdapse (3,4-diaminopyridine or 3,4-DAP)
- Ruzurgi (amifampridine)